Patents by Inventor Tal Atarot

Tal Atarot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10046032
    Abstract: The present disclosure provides means and methods for promoting gastric emptying. In particular, the present disclosure provides the use of insulin or a composition comprising same for promoting gastric emptying and for treating gastric disorders, particularly disorders characterized by delayed gastric emptying. The insulin or composition comprising same are to be administered enterally.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Nutrinia, LTD.
    Inventors: Tal Atarot, Michal Olshansky
  • Publication number: 20170319663
    Abstract: The present disclosure provides means and methods for promoting gastric emptying. In particular, the present disclosure provides the use of insulin or a composition comprising same for promoting gastric emptying and for treating gastric disorders, particularly disorders characterized by delayed gastric emptying. The insulin or composition comprising same are to be administered enterally.
    Type: Application
    Filed: March 24, 2017
    Publication date: November 9, 2017
    Inventors: Tal ATAROT, Michal OLSHANSKY
  • Patent number: 9370481
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: June 21, 2016
    Assignee: Vecta, Ltd.
    Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
  • Patent number: 9233092
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustained enhancement effect on the PPI activity compared to the non-derivatized acid molecules. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: January 12, 2016
    Assignee: Vecta, Ltd.
    Inventors: Michael Marash, Aleksey Kostadinov, Tal Atarot
  • Patent number: 9132082
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+ ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 15, 2015
    Assignee: Vecta, Ltd.
    Inventors: Aleksey Kostadinov, Tal Atarot, Michael Naveh
  • Publication number: 20110250268
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Application
    Filed: April 19, 2011
    Publication date: October 13, 2011
    Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
  • Patent number: 7981908
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: July 19, 2011
    Assignee: Vecta, Ltd.
    Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
  • Publication number: 20110111039
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Application
    Filed: May 14, 2009
    Publication date: May 12, 2011
    Inventors: Aleksey Kostadinov, Tal Atarot, Michael Naveh
  • Publication number: 20080248109
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Application
    Filed: May 14, 2008
    Publication date: October 9, 2008
    Applicant: VECTA, LTD.
    Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot